The level of serum Visfatin in type 2 diabetes mellitus and the effect of short-term rosiglitazone on it
- VernacularTitle:2型糖尿病患者血清Visfatin浓度测定及罗格列酮治疗的影响
- Author:
Wenjun WU
;
Weiping LI
;
Dawang WANG
- Publication Type:Journal Article
- Keywords:
Diabetesmellitus,type2;
Visfatin;
Insulin resistance;
Rosiglitazone
- From:
Chinese Journal of Postgraduates of Medicine
2008;31(31):24-27
- CountryChina
- Language:Chinese
-
Abstract:
Objective To determine the serum level of Visfatin, and observe the effect of short-term treatment of rosiglitazone on it in the patients with type 2 diabetes mellitus. Methods Thirty-three patients with type 2 diahetes mellitus(diabetic group) who were inadequately controlled by suffonylureas were treated with rosiglitazone (4 mg/d) for 12 weeks. Twenty-seven sex-, age- and BMI-matehed non-diabetic subjects (control group) were studied. Determined blood pressure, Visfatin, triglyceride (TG), high density lipopro-tein cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C), fasting plasma glucose (FPG),2-hoar postprandial glucose (2 h PPG), fasting insulin (FINS)in all subjects and free fatty acid (FFA), high sensitive C-reactlve protein (hs-CRP) and glyeosylated hemoglobin (GHbA1c), abdominal fat distribution before and after treatment with rosiglitazone in diabetic group respectively. Results The level of serum Visfatin was lower in diabetic group than that in control group [(24.53±9.22) μg/L vs (53.10±27.00)μg/L, P<0.01 ], and it was higher after treatment with rosiglitazone for 12 weeks, but there was no significant difference [(24.53±9.22)μg/L vs (32.62±24.89) μg/L, P>0.05]. Visfatin was correlated significantly with systolic pressure (r =-0.29, P=0.02), FPG (r=-0.40, P=0.001 ), 2 h PPG (r=-0.34, P=0.009 ),LDL-C (r=0.26,P=0.049) and FFA (r=0.44,P=0.009) respectively. In a linear stepwise regression analysis, FFA showed significant correlation with serum Visfatin levels (r2=0.30,f=7.707, P=0.009).Conclusions The level of serum Visfatin is lower in type 2 diabetes mellitus, and it is related significantly with glucose and lipid metabolic factors. The short-term treatment with rosiglitazone can't increase the serum concentration of Visfatin in the type 2 diabetes mellitua.
